Re: Catherine H. Marshall, Alexandra O. Sokolova, Andrea L. McNatty, et al. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. Eur Urol 2019;76:452–8
Liang J, Beckta JM, Bindra RS. Re: Catherine H. Marshall, Alexandra O. Sokolova, Andrea L. McNatty, et al. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. Eur Urol 2019;76:452–8. European Urology 2019, 76: e109-e110. PMID: 31080125, DOI: 10.1016/j.eururo.2019.04.041.Peer-Reviewed Original ResearchMeSH KeywordsAtaxia Telangiectasia Mutated ProteinsBRCA1 ProteinBRCA2 ProteinHumansMaleMutationPhthalazinesPiperazinesProstatic Neoplasms, Castration-ResistantConceptsOlaparib treatment